Eledon Pharmaceuticals Inc

NASDAQ ELDN

Download Data

Eledon Pharmaceuticals Inc Net Debt to EBITDA Ratio 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -81.59%

Eledon Pharmaceuticals Inc Net Debt to EBITDA Ratio 3 year CAGR is -81.59% for the Trailing 12 Months (TTM) ending March 31, 2024, a -539.58% change year over year. The net debt to EBITDA ratio measures the level of a company's net debt relative to its earnings before interest, taxes, depreciation, and amortization (EBITDA). It is calculated by dividing the net debt (total debt minus cash and cash equivalents) by EBITDA. This ratio provides insights into the company's ability to repay its debt using its operating earnings. A higher ratio indicates a higher level of debt relative to earnings, suggesting potential financial risk and difficulty in debt repayment. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Eledon Pharmaceuticals Inc Net Debt to EBITDA Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 5.89, a -38.81% change year over year.
  • Eledon Pharmaceuticals Inc Net Debt to EBITDA Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 9.62, a -52.65% change year over year.
  • Eledon Pharmaceuticals Inc Net Debt to EBITDA Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 20.32, a 475.18% change year over year.
  • Eledon Pharmaceuticals Inc Net Debt to EBITDA Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 3.53, a -7.69% change year over year.
NASDAQ: ELDN

Eledon Pharmaceuticals Inc

CEO Dr. David-Alexandre C. Gros M.D., Ph.D.
IPO Date Sept. 17, 2014
Location United States
Headquarters 19900 MacArthur Boulevard, Irvine, CA, United States, 92612
Employees 20
Sector Healthcare
Industry Biotechnology
Description

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

ABOS

Acumen Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email